Cargando…

Immune checkpoint inhibition in advanced esophageal squamous cell carcinoma: how can we personalise management?

Detalles Bibliográficos
Autores principales:	Cagney, Hannah P., Petty, Russell D., Baxter, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407481/ https://www.ncbi.nlm.nih.gov/pubmed/37559602 http://dx.doi.org/10.21037/jtd-23-598

Ejemplares similares

Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
por: Baxter, Mark A., et al.
Publicado: (2021)

How we treat esophageal squamous cell carcinoma
por: Puhr, H.C., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Personalised medicine: are we ready?
por: Louis, Renaud, et al.
Publicado: (2017)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
por: Longhitano, Elisa, et al.
Publicado: (2023)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
por: Zhang, Wencheng, et al.
Publicado: (2020)

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
por: Wessely, Anja, et al.
Publicado: (2020)

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
por: Zhao, Jing-Jing, et al.
Publicado: (2018)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
por: Vivaldi, Caterina, et al.
Publicado: (2020)

Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
por: Chen, Ning, et al.
Publicado: (2023)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

“Advances in Preterm Delivery”—How Can We Advance Further?
por: Wainstock, Tamar, et al.
Publicado: (2022)

Successful immune checkpoint inhibitor‐based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report
por: Yao, Yanhong, et al.
Publicado: (2022)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
por: Baxter, Mark A., et al.
Publicado: (2020)

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
por: Jordan, B., et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
por: Jiang, Mengjie, et al.
Publicado: (2023)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Can Opioid-Free Anaesthesia Be Personalised? A Narrative Review
por: Goff, Jenna, et al.
Publicado: (2023)

Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
por: Yiong, Chin Sern, et al.
Publicado: (2023)

Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
por: Zhang, Zhengfeng, et al.
Publicado: (2023)

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition
por: Donlon, Noel E., et al.
Publicado: (2022)

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
por: von der Grün, Jens, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

How Can We Diagnose Ocular Surface Squamous Neoplasia With Optical Coherence Tomography?
por: Başkan, Ceyda, et al.
Publicado: (2023)

Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups
por: Yap, Dominic Wei Ting, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
por: Kao, Ming-Wei, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
por: Renner, Alex, et al.
Publicado: (2019)

Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma
por: Xiao, Linlin, et al.
Publicado: (2022)

Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
por: Cristancho, Cagney, et al.
Publicado: (2020)

Goal directed therapy: how long can we wait?
por: Gordon, Anthony C, et al.
Publicado: (2005)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iqq092ogpjaticgdecek62ai33